<DOC>
	<DOCNO>NCT02910999</DOCNO>
	<brief_summary>This study intend describe real-life effectiveness safety nivolumab advance NSCLC patient Germany , well patient profile , pattern use quality life .</brief_summary>
	<brief_title>Real-Life Study With Nivolumab ( BMS-936558 ) Advanced NSCLC Patients After Prior Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis locally advance metastatic NSCLC , Stage IIIB/Stage IV 2 . Decision initiate treatment Nivolumab first time already undertaken physician 3 . Males Females , â‰¥18 year age 1 . Current primary diagnosis cancer advance NSCLC . Example : A cancer NSCLC require systemic treatment . 2 . Pretreatment Nivolumab and/or Ipilimumab ( pretreatment checkpointinhibitors Nivolumab Ipilimumab , Tyrosine Kinase Inhibitors ( TKIs ) allow ) 3 . Current participation interventional clinical trial treatment NSCLC . ( Patients complete participation interventional trial receive study drug anymore followedup overall survival enrol . For blinded study , treatment administer need know )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>